X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will be used to support the clinical development of ALLO-316, an AlloCAR T™ investigational product targeting CD70 in development for the treatment of advanced or metastatic renal cell carcinoma.
Lead Product(s): ALLO-316,ALLO-647,Cyclophosphamide
Therapeutic Area: Oncology Product Name: ALLO-316
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: California Institute for Regenerative Medicine
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Funding April 26, 2024
Details:
Under the agreement, Allogene will use Arbor’s proprietary CRISPR gene-editing technology in its next generation AlloCAR T platform, ALLO-329, for the treatment of autoimmune disease (AID).
Lead Product(s): ALLO-329
Therapeutic Area: Immunology Product Name: ALLO-329
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Recipient: Arbor Biotechnologies, Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 12, 2024
Details:
ALLO-501A (cemacabtagene ansegedleucel) isbeing evaluated in clinical studies for the treatment of patients with Relapsed/Refractory Large B-Cell Lymphoma (LBCL).
Lead Product(s): Cemacabtagene Ansegedleucel,ALLO-647,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: ALLO-501A
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2024
Details:
ALLO-316, an AlloCAR T investigational product targets CD70, which is highly expressed in RCC. CD70 is also selectively expressed in several cancers, creating the potential for ALLO-316 to be developed across a variety of both hematologic malignancies and solid tumors.
Lead Product(s): ALLO-316,ALLO-647,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: ALLO-316
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2023
Details:
The selection of ALLO-213 was based on potency and specificity against SCLC cell lines in vitro and in vivo, including cell lines with very low antigen density to establish sensitivity.
Lead Product(s): ALLO-213
Therapeutic Area: Oncology Product Name: ALLO-213
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2023
Details:
ALLO-715 is an anti-BCMA (B-cell maturation antigen) AlloCAR T therapy product candidate which is being developed as a potential novel treatment for multiple myeloma and other BCMA-positive malignancies.
Lead Product(s): ALLO-715,ALLO-647,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: ALLO-715
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2023
Details:
UNIVERSAL is the first trial to demonstrate significant responses can be achieved with an allogeneic CAR T product candidate. ALLO-715, an anti-BCMA AlloCAR T product candidate for relapsed/refractory multiple myeloma.
Lead Product(s): ALLO-715,ALLO-647,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: ALLO-715
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
CAR T Together™ is a first-of-its-kind effort representing the many investigators who are committed to supporting the development of “off-the-shelf” (allogeneic) CAR T products that are scalable and faster to deliver – making treatments accessible to more cancer patients.
Lead Product(s): Allogeneic CAR-T Cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2022
Details:
ALPHA2 Trial, Evaluating ALLO-501A in Relapsed/Refractory Large B Cell Lymphoma Patients, is Designed to Leverage the Ease and Convenience of a Single Dose of ALLO-501A.
Lead Product(s): ALLO-501A,ALLO-647,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: ALLO-501A
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2022
Details:
ALLO-605 is the Company’s first TurboCAR™ product candidate. TurboCAR™ is a proprietary, next generation platform technology based on a programmable cytokine signaling, designed to control T cell exhaustion and to improve T cell function and potency.
Lead Product(s): ALLO-605,ALLO-647,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: ALLO-605
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
